Live Breaking News & Updates on கீமோதெரபி

Stay updated with breaking news from கீமோதெரபி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Bevacizumab Misses Mark in Untreated Metastatic Bladder Cancer


email article
Adding a targeted agent to chemotherapy failed to improve survival as initial therapy for metastatic urothelial carcinoma, a randomized trial showed.
Median overall survival (OS) was about 14 months with cisplatin-containing chemotherapy when paired with either placebo or the angiogenesis inhibitor bevacizumab (Avastin). Progression-free survival (PFS), a secondary endpoint, favored the bevacizumab arm (8.0 vs 6.7 months).
Grade ≥3 adverse events (AEs) occurred in a similar proportion of patients in each arm, although bevacizumab-related toxicities occurred more often with the addition of the angiogenesis inhibitor, reported Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center in New York City, and colleagues, in the ....

New York , United States , Memorial Sloan Kettering Cancer Center , Jonathane Rosenberg , Charles Bankhead , Arjun Balar , Langone Health , New York City , Medpage Today , Bladder Cancer , Urothelial Carcinoma , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , நினைவகம் ஸ்லோன் கெட்டரிங் புற்றுநோய் மையம் , சார்லஸ் வங்கித் தலை , அர்ஜுன் பாலார் , லன்கொனே ஆரோக்கியம் , புதியது யார்க் நகரம் , சிறுநீர்ப்பை புற்றுநோய் ,